ITPRIPL1 and neoplasm: Recent studies have identified ITPRIPL1, a newly reported CD3ε‐inhibitory ligand, as a suppressor of T cell activation, thereby facilitating tumor immune evasion and offering a novel avenue for immunotherapeutic intervention in glioma.